Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-12
DOI
10.1097/meg.0000000000002656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
- (2023) Federico Ravaioli et al. GUT
- AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
- (2023) Mary E. Rinella et al. HEPATOLOGY
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
- (2023) Zobair M. Younossi et al. HEPATOLOGY
- Rational Combination Therapy for NASH: Insights from Clinical Trials and Error
- (2023) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry
- (2023) Andreas Geier et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
- (2023) Daniel Q. Huang et al. GASTROENTEROLOGY
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
- (2023) Rohit Loomba et al. Lancet Gastroenterology & Hepatology
- Clinical Trial Landscape in NASH
- (2023) Stephen A. Harrison et al. Clinical Gastroenterology and Hepatology
- Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
- (2022) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
- (2022) Kenneth Cusi et al. Endocrine Practice
- Cohort Profile: The LIFE-Adult-Study
- (2022) Christoph Engel et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Breakthroughs in therapies for NASH and remaining challenges
- (2022) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
- (2022) Alina M. Allen et al. JOURNAL OF HEPATOLOGY
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025
- (2022) et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
- (2022) Arun J. Sanyal et al. JOURNAL OF HEPATOLOGY
- The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
- (2021) Giovanni Targher et al. Nature Reviews Gastroenterology & Hepatology
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
- (2021) Annalisa Berzigotti et al. JOURNAL OF HEPATOLOGY
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
- (2021) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis
- (2020) Anna Roskilly et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
- (2020) Philip N Newsome et al. Lancet Gastroenterology & Hepatology
- Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
- (2020) Florian Gerhardt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
- (2020) Rebecca K. Vincent et al. DIABETES OBESITY & METABOLISM
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes mellitus is a risk factor for progression of liver fibrosis in middle‐aged patients with nonalcoholic fatty liver disease
- (2019) Toshifumi Tada et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non‐alcoholic Fatty Liver Disease
- (2019) Fasiha Kanwal et al. HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2018) Zobair M. Younossi et al. HEPATOLOGY
- Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany
- (2018) Christian Labenz et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Guidelines on the management of abnormal liver blood tests
- (2017) Philip N Newsome et al. GUT
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- (2016) Stuart McPherson et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques
- (2015) Thomas Karlas WORLD JOURNAL OF GASTROENTEROLOGY
- The effect of rate of weight loss on long-term weight management: a randomised controlled trial
- (2014) Katrina Purcell et al. Lancet Diabetes & Endocrinology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now